France’s Ipsen SA is delivering on one of its strategic aims, to build up its early clinical R&D pipeline in a small number of targeted therapeutic areas including neuroscience, by licensing exclusive worldwide rights to IRLAB Therapeutics AB’s clinical-stage candidate, mesdopetam, for use in Parkinson’s disease.
Mesdopetam (IRL-790) appears to be in the sweet-spot of Paris-headquartered Ipsen, being a novel, oral, dopamine D3-receptor antagonist which has...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
